Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Irritable Bowel Syndrome HELP
Based on 4,606 articles published since 2007
||||

These are the 4606 published articles about Irritable Bowel Syndrome that originated from Worldwide during 2007-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Pharmacologic Management of Irritable Bowel Syndrome. 2015

Rao, Vijaya L / Cifu, Adam S / Yang, Leslie W / Anonymous6260853. ·Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Illinois. · Section of General Internal Medicine, University of Chicago Medical Center, Chicago, Illinois. · ·JAMA · Pubmed #26720029.

ABSTRACT: -- No abstract --

2 Guideline Evidence-based clinical practice guidelines for irritable bowel syndrome. 2015

Fukudo, Shin / Kaneko, Hiroshi / Akiho, Hirotada / Inamori, Masahiko / Endo, Yuka / Okumura, Toshikatsu / Kanazawa, Motoyori / Kamiya, Takeshi / Sato, Ken / Chiba, Toshimi / Furuta, Kenji / Yamato, Shigeru / Arakawa, Tetsuo / Fujiyama, Yoshihide / Azuma, Takeshi / Fujimoto, Kazuma / Mine, Tetsuya / Miura, Soichiro / Kinoshita, Yoshikazu / Sugano, Kentaro / Shimosegawa, Tooru. ·Guidelines Committee for creating and evaluating the "Evidence-based clinical practice guidelines for irritable bowel syndrome", the Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13 Ginza, Chuo, Tokyo, 104-0061, Japan, sfukudo@med.tohoku.ac.jp. · ·J Gastroenterol · Pubmed #25500976.

ABSTRACT: New strategies for the care of irritable bowel syndrome (IBS) are developing and several novel treatments have been globally produced. New methods of care should be customized geographically because each country has a specific medical system, life style, eating habit, gut microbiota, genes and so on. Several clinical guidelines for IBS have been proposed and the Japanese Society of Gastroenterology (JSGE) subsequently developed evidence-based clinical practice guidelines for IBS. Sixty-two clinical questions (CQs) comprising 1 definition, 6 epidemiology, 6 pathophysiology, 10 diagnosis, 30 treatment, 4 prognosis, and 5 complications were proposed and statements were made to answer to CQs. A diagnosis algorithm and a three-step treatment was provided for patients with chronic abdominal pain or abdominal discomfort and/or abnormal bowel movement. If more than one alarm symptom/sign, risk factor and/or routine examination is positive, colonoscopy is indicated. If all of them, or the subsequent colonoscopy, are/is negative, Rome III or compatible criteria is applied. After IBS diagnosis, step 1 therapy consisting of diet therapy, behavioral modification and gut-targeted pharmacotherapy is indicated for four weeks. Non-responders to step 1 therapy proceed to the second step that includes psychopharmacological agents and simple psychotherapy for four weeks. In the third step, for patients non-responsive to step 2 therapy, a combination of gut-targeted pharmacotherapy, psychopharmacological treatments and/or specific psychotherapy is/are indicated. Clinical guidelines and consensus for IBS treatment in Japan are well suited for Japanese IBS patients; as such, they may provide useful insight for IBS treatment in other countries around the world.

3 Guideline The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. 2014

Dumitrascu, Dan L / Chira, Alexandra / Bataga, Simona / Diculescu, Mircea / Drug, Vasile / Gheorghe, Cristian / Goldis, Adrian / Nedelcu, Laurentiu / Porr, Paul J / Sporea, Ioan / Anonymous1520816. ·2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro. · 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · University of Medicine and Pharmacy, Tg-Mures, Romania. · Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. · Gr. T. Popa University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania. · Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timisoara, Romania. · Department of Internal Medicine, Transilvania University, Brasov, Romania. · Lucian Blaga University, Sibiu, Romania. · ·J Gastrointestin Liver Dis · Pubmed #25532003.

ABSTRACT: -- No abstract --

4 Guideline American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. 2014

Weinberg, David S / Smalley, Walter / Heidelbaugh, Joel J / Sultan, Shahnaz / Anonymous4540806. ·Fox Chase Cancer Center, Philadelphia, Pennsylvania. · VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee. · University of Michigan Ann Arbor, Michigan. · Department of Veterans Affairs Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota. · ·Gastroenterology · Pubmed #25224526.

ABSTRACT: -- No abstract --

5 Guideline [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)]. 2013

Andresen, V / Layer, P / Anonymous3840776 / Anonymous3850776 / Anonymous3860776. · ·Z Gastroenterol · Pubmed #24266047.

ABSTRACT: -- No abstract --

6 Guideline Intestinal microbiota in functional bowel disorders: a Rome foundation report. 2013

Simrén, Magnus / Barbara, Giovanni / Flint, Harry J / Spiegel, Brennan M R / Spiller, Robin C / Vanner, Stephen / Verdu, Elena F / Whorwell, Peter J / Zoetendal, Erwin G / Anonymous5510729. ·Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-41345, Sweden. magnus.simren@medicine.gu.se · ·Gut · Pubmed #22730468.

ABSTRACT: It is increasingly perceived that gut host-microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host-microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.

7 Guideline British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. 2012

McKenzie, Y A / Alder, A / Anderson, W / Wills, A / Goddard, L / Gulia, P / Jankovich, E / Mutch, P / Reeves, L B / Singer, A / Lomer, M C E / Anonymous990723. ·Nuffield Health The Manor Hospital, Oxford, UK Department of Nutrition and Dietetics, Royal Sussex County Hospital, Brighton, UK. · ·J Hum Nutr Diet · Pubmed #22489905.

ABSTRACT: BACKGROUND:  Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder. Diet and lifestyle changes are important management strategies. The aim of these guidelines is to systematically review key aspects of the dietary management of IBS, with the aim of providing evidence-based guidelines for use by registered dietitians. METHODS: Questions relating to diet and IBS symptom management were developed by a guideline development group. These included the role of milk and lactose, nonstarch polysaccharides (NSP), fermentable carbohydrates in abdominal bloating, probiotics and empirical or elimination diets. A comprehensive literature search was conducted and relevant studies from January 1985 to November 2009 were identified using the electronic database search engines: Cinahl, Cochrane Library, Embase, Medline, Scopus and Web of Science. Evidence statements, recommendations, good practice points and research recommendations were developed. RESULTS: Thirty studies were critically appraised. A dietetic care pathway was produced following a logical sequence of treatment and formed the basis of these guidelines. Three lines of dietary management were identified. first line: Clinical and dietary assessment, healthy eating and lifestyle management with some general advice on lactose and NSP. Second line: Advanced dietary interventions to improve symptoms based on NSP, fermentable carbohydrates and probiotics. Third line: Elimination and empirical diets. Research recommendations were also identified relating to the need for adequately powered and well designed randomised controlled trials. CONCLUSIONS: These guidelines provide evidence-based details of how to achieve the successful dietary management of IBS.

8 Guideline [IBD ahead 2010--Answering important questions in Crohn's disease treatment]. 2011

Schmidt, C / Dignass, A / Hartmann, F / Hüppe, D / Kruis, W / Layer, P / Lüers, A / Stallmach, A / Teich, N / Sturm, A / Anonymous6220703. ·Universitätklinikum Jena, Klinik für Innere Medizin II, Abteilung für Gastroenterologie, Hepatologie und Infektiologie. · ·Z Gastroenterol · Pubmed #21866492.

ABSTRACT: The treatment of patients with inflammatory bowel disease has become more complex in recent years through the introduction of various immunosuppressive agents as well as the approval of monoclonal antibodies against TNF-α and patients receiving such treatment must be carefully monitored. National and international guidelines define a diagnostic and therapeutic context for the practitioner, but can only partially respond to specific questions on the procedure for individual patients. Within the framework of a project initiated by Abbott entitled "IBD ahead" 38 German IBD experts have elaborated concrete proposals for dealing with corticosteroids, immunosuppressants and TNF-α antibodies on the basis of the published literature and their own personal experience in order to close the gap between these guidelines and daily clinical practice. Statements were developed on the choice of correct timing of initiation, dose and duration of the individual substances and on how to proceed with patients exhibiting treatment failure. Moreover, recommendations are also made on drug combination strategies, safety monitoring and the risks regarding the development of infectious complications and malignancies. These recommendations are illustrated by case studies from everyday practice in participating centres.

9 Guideline [Guidelines for the treatment of irritable bowel syndrome]. 2011

Kwon, Joong Goo / Park, Kyung Sik / Park, Jung Ho / Park, Jae Myung / Park, Cheol Hee / Lee, Kwang Jae / Park, Hyo Jin / Rhee, Jong Chul / Anonymous4200687. ·Department of Internal Medicine, Catholic University of Daegu School of Medicine, Korea. · ·Korean J Gastroenterol · Pubmed #21350320.

ABSTRACT: Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT((4)) receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.

10 Guideline [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. 2011

Layer, P / Andresen, V / Pehl, C / Allescher, H / Bischoff, S C / Classen, M / Enck, P / Frieling, T / Haag, S / Holtmann, G / Karaus, M / Kathemann, S / Keller, J / Kuhlbusch-Zicklam, R / Kruis, W / Langhorst, J / Matthes, H / Mönnikes, H / Müller-Lissner, S / Musial, F / Otto, B / Rosenberger, C / Schemann, M / van der Voort, I / Dathe, K / Preiss, J C / Anonymous5280685 / Anonymous5290685. ·Für die Konsensusgruppe Reizdarmsyndrom; Konsensuskonferenz 18./ 19.9.2009. layer@ik-h.de · ·Z Gastroenterol · Pubmed #21287438.

ABSTRACT: -- No abstract --

11 Guideline Asian consensus on irritable bowel syndrome. 2010

Gwee, Kok-Ann / Bak, Young-Tae / Ghoshal, Uday Chand / Gonlachanvit, Sutep / Lee, Oh Young / Fock, Kwong Ming / Chua, Andrew Seng Boon / Lu, Ching-Liang / Goh, Khean-Lee / Kositchaiwat, Chomsri / Makharia, Govind / Park, Hyo-Jin / Chang, Full-Young / Fukudo, Shin / Choi, Myung-Gyu / Bhatia, Shobna / Ke, Meiyun / Hou, Xiaohua / Hongo, Michio / Anonymous5550664. ·Stomach Liver and Bowel Clinic, Gleneagles Hospital, Singapore. slbclinic@gmail.com · ·J Gastroenterol Hepatol · Pubmed #20594245.

ABSTRACT: BACKGROUND AND AIMS: Many of the ideas on irritable bowel syndrome (IBS) are derived from studies conducted in Western societies. Their relevance to Asian societies has not been critically examined. Our objectives were to bring to attention important data from Asian studies, articulate the experience and views of our Asian experts, and provide a relevant guide on this poorly understood condition for doctors and scientists working in Asia. METHODS: A multinational group of physicians from Asia with special interest in IBS raised statements on IBS pertaining to symptoms, diagnosis, epidemiology, infection, pathophysiology, motility, management, and diet. A modified Delphi approach was employed to present and grade the quality of evidence, and determine the level of agreement. RESULTS: We observed that bloating and symptoms associated with meals were prominent complaints among our IBS patients. In the majority of our countries, we did not observe a female predominance. In some Asian populations, the intestinal transit times in healthy and IBS patients appear to be faster than those reported in the West. High consultation rates were observed, particularly in the more affluent countries. There was only weak evidence to support the perception that psychological distress determines health-care seeking. Dietary factors, in particular, chili consumption and the high prevalence of lactose malabsorption, were perceived to be aggravating factors, but the evidence was weak. CONCLUSIONS: This detailed compilation of studies from different parts of Asia, draws attention to Asian patients' experiences of IBS.

12 Guideline Guidelines on the irritable bowel syndrome: mechanisms and practical management. 2007

Spiller, R / Aziz, Q / Creed, F / Emmanuel, A / Houghton, L / Hungin, P / Jones, R / Kumar, D / Rubin, G / Trudgill, N / Whorwell, P / Anonymous4990567. ·Wolfson Digestive Diseases Centre, University of Nottingham, Nottingham, UK. robin.spiller@nottingham.ac.uk · ·Gut · Pubmed #17488783.

ABSTRACT: BACKGROUND: IBS affects 5-11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance. AIM: To provide a guide for the assessment and management of adult patients with irritable bowel syndrome. METHODS: Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases. RESULTS: Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients' concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT(3) antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT(4) agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms. CONCLUSIONS: Better ways of identifying which patients will respond to specific treatments are urgently needed.

13 Editorial Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? 2017

Black, C J / Ford, A C. ·Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK. ·Aliment Pharmacol Ther · Pubmed #28880445.

ABSTRACT: -- No abstract --

14 Editorial Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply. 2017

Polster, A / Van Oudenhove, L / Jones, M / Öhman, L / Törnblom, H / Simrén, M. ·Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Gothenburg, Sweden. · Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium. · Psychology Department, Macquarie University, North Ryde, NSW, Australia. · Department of Microbiology and Immunology, Sahlgrenska Academy, Gothenburg, Sweden. · Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Gothenburg, Sweden.; Center for Functional Gastrointestinal and Motility Disorders, Chapel Hill, NC, USA. ·Aliment Pharmacol Ther · Pubmed #28880440.

ABSTRACT: -- No abstract --

15 Editorial Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply. 2017

Alexakis, C / Kumar, S / Saxena, S / Hotopf, M / Pollok, R. ·Department of Gastroenterology, St George's University NHS Hospitals Trust, London, UK. · Department of Primary Care and Public Health, Imperial College London, London, UK. · Department of Psychological Medicine, King's College Hospital, London, UK. ·Aliment Pharmacol Ther · Pubmed #28776734.

ABSTRACT: -- No abstract --

16 Editorial Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply. 2017

Damas, Oriana M / Schwartz, Seth J / Abreu, Maria T. ·Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. · Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. ·Aliment Pharmacol Ther · Pubmed #28707792.

ABSTRACT: -- No abstract --

17 Editorial Editorial: food for thought-the low-FODMAP diet and IBS in perspective. 2017

Quigley, E M M. ·Division of Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. ·Aliment Pharmacol Ther · Pubmed #28621070.

ABSTRACT: -- No abstract --

18 Editorial Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply. 2017

Sood, R / Gracie, D J / Gold, M J / To, N / Pinto-Sanchez, M I / Bercik, P / Moayyedi, P / Ford, A C / Law, G R. ·Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK. · School of Medicine, University of Leeds, Leeds, UK. · Gastroenterology Division, Health Sciences Center, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. · Division of Epidemiology & Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. ·Aliment Pharmacol Ther · Pubmed #28370047.

ABSTRACT: -- No abstract --

19 Editorial Editorial: latent class analysis to improve confidence in the diagnosis of IBS. 2017

Ballou, S / Lembo, A. ·Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ·Aliment Pharmacol Ther · Pubmed #28370041.

ABSTRACT: -- No abstract --

20 Editorial Editorial: diet, inflammation and irritable bowel syndrome. 2017

Quigley, E M M. ·Lynda K and David M Underwood Center for Digestive Disorders, Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. ·Aliment Pharmacol Ther · Pubmed #28370035.

ABSTRACT: -- No abstract --

21 Editorial Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply. 2017

Whitehead, W E / Duffy, K / Sharpe, J / Nabata, T / Bruce, M. ·Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · Ono Pharma UK Ltd, London, UK. ·Aliment Pharmacol Ther · Pubmed #28256085.

ABSTRACT: -- No abstract --

22 Editorial Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea. 2017

Nee, J / Lembo, A. ·Beth Israel Deaconess Medical Center - Gastroenterology, Boston, MA, USA. ·Aliment Pharmacol Ther · Pubmed #28256084.

ABSTRACT: -- No abstract --

23 Editorial Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome? 2017

Staudacher, H M / Cox, S R. ·Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia. · King's College London, Faculty of Life Sciences and Medicine, London, UK. ·Aliment Pharmacol Ther · Pubmed #28256083.

ABSTRACT: -- No abstract --

24 Editorial Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. Authors' reply. 2017

Xu, X J / Yao, S K. ·Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.; Gastroenterology Department, China-Japan Friendship Hospital, Beijing, China. ·Aliment Pharmacol Ther · Pubmed #28074518.

ABSTRACT: -- No abstract --

25 Editorial Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. 2017

Bennet, S M P / Törnblom, H. ·Department of Internal Medicine & Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ·Aliment Pharmacol Ther · Pubmed #28074514.

ABSTRACT: -- No abstract --

Next